ライフサイエンスコーパス: chondroitin sulfate

1 o showed increased decorin and production of chondroitin sulfate.

2 old) toward heparin over hyaluronic acid and chondroitin sulfate.

3 cosaminoglycans, such as hyaluronic acid and chondroitin sulfate.

4 onic Hh complexes with two GAGs, heparin and chondroitin sulfate.

5 cylation, increased synthesis of both HA and chondroitin sulfate.

6 dulterant or contaminant, e.g., oversulfated chondroitin sulfate.

7 rization in solution, which was inhibited by chondroitin sulfate.

8 ran sulfate (HS), dermatan sulfate (DS), and chondroitin sulfate.

9 parin > dermatan sulfate > heparan sulfate > chondroitin sulfate.

10 athepsin K is not affected by the binding of chondroitin sulfate.

11 sulting from contamination with oversulfated chondroitin sulfate.

12 nts of heparin accompanied by a reduction of chondroitin sulfate.

13 ycosaminoglycans such as heparan sulfate and chondroitin sulfate.

14 ocytosis of HA, Hep, AcLDL, or DS but not by chondroitin sulfates.

15 ree than on surfaces coated with dermatan or chondroitin sulfates.

16 arin, heparan sulfate, dermatan sulfate, and chondroitin sulfates.

17 fixed combination of xanthan gum 0.09 % and chondroitin sulfate 0.1 % (XG/CS) ophthalmic solution (n

18 Chondroitin sulfate A (CS-A, also known as chondroitin-4

19 tan sulfate (KS), dermatan sulfate (DS), and chondroitin sulfate A (CSA) and C (CSC), polymerized in

20 erythrocytes (IEs) that selectively bind to chondroitin sulfate A (CSA) and sequester in placental t

21 ocytes that adhere to the placental receptor chondroitin sulfate A (CSA) and sequester in the placent

22 ciparum-infected erythrocytes, and placental chondroitin sulfate A (CSA) are primarily responsible fo

23 ncipal ligand associated with the binding to chondroitin sulfate A (CSA) that allows placental seques

24 alciparum-infected erythrocytes to placental chondroitin sulfate A (CSA) through the PfEMP1-VAR2CSA p

25 glycans (GAGs) include keratan sulfate (KS), chondroitin sulfate A (CSA), and hyaluronic acid (HA).

26 hesion of VAR2CSA-expressing erythrocytes to chondroitin sulfate A (CSA)-a major criterion for evalua

27 serum cross-reacted with surface proteins of chondroitin sulfate A (CSA)-binding laboratory strains (

28 chia pastoris and developed a panel of seven chondroitin sulfate A (CSA)-binding parasites from diver

29 2CSA, a parasite antigen that interacts with chondroitin sulfate A (CSA).

30 ythrocytes (IEs) with the ability to bind to chondroitin sulfate A (CSA).

31 he presence of the contaminant, oversulfated chondroitin sulfate A (OSCS), in heparin.

32 over dextran sulfate, dermatan sulfate, and chondroitin sulfate A and C.

33 thereby promoting amyloid formation, whereas chondroitin sulfate A kinetically traps partially unfold

34 Second, C1INH bound to host CD36 and chondroitin sulfate A molecules, interfering with cytoad

35 e antigen VAR2CSA (variant surface antigen 2-chondroitin sulfate A) is expressed on infected erythroc

36 be our results of HC transfer experiments to chondroitin sulfate A, chemically desulfated chondroitin

37 major glycosaminoglycans, including heparin, chondroitin sulfate A, dermatan sulfate, and OSCS.

38 ed multivariate analysis, including heparin, chondroitin sulfate A, dermatan sulfate, and the infamou

39 d, partially sulfated, or fully oversulfated chondroitin sulfate A, dermatan sulfate, or heparan sulf

40 variant surface antigen that binds placental chondroitin sulfate A, have been suggested to mediate pr

41 escribes the separation of dermatan sulfate, chondroitin sulfate A, heparin, and the semisynthetic fu

42 of Hic to hTSP-1 is inhibited by heparin and chondroitin sulfate A, indicating binding to the N-termi

43 nfected erythrocytes and mediates binding to chondroitin sulfate A, initiating inflammation and disru

44 Chondroitin sulfate A, on the other hand, showed a stron

45 the actions of these two exolytic lyases on chondroitin sulfate A.

46 (IEs) that surface-express VAR2CSA and bind chondroitin sulfate A.

47 basic peptides (FS2 and NFS3) to heparin and chondroitin sulfate A.

48 e-3-phosphate dehydrogenase aggregation, but chondroitin sulfates A, B, and C together with dextran s

49 Chondroitin sulfate, a common dietary supplement, increa

50 Copigmented complexes of chondroitin sulfate and anthocyanin were preloaded in Ca

51 ibrin(ogen) is predominantly mediated by the chondroitin sulfate and dermatan sulfate on CD44.

52 ne a key requirement for the balance between chondroitin sulfate and heparan sulfate chains in dictat

53 pparent M(r) > 200,000 and are modified with chondroitin sulfate and heparan sulfate chains.

54 e in HSV binding, we tested two native GAGs (chondroitin sulfate and heparan sulfate) and compared ou

55 Native chondroitin sulfate and heparin oligosaccharides as well

56 negatively charged glycosaminoglycans (GAGs) chondroitin sulfate and high-molecular-weight hyaluronan

57 muc bound via the expected binding region to chondroitin sulfate and sulfated hyaluronan but not to t

58 phy, we demonstrate that S. rosetta produces chondroitin sulfate and thus extend the ancestry of this

59 reducing glial scar volume and expression of chondroitin sulfates and the chondroitin sulfate proteog

60 s, hyaluronan, heparan sulfate, heparin, and chondroitin sulfate, and collagen-like peptides as physi

61 f cell-specific GAG chains (heparan sulfate, chondroitin sulfate, and dermatan sulfate) with distinct

62 Our data suggest that IAIP, chondroitin sulfate, and HMW-HA are potential therapeuti

63 e samples to determine GAG (heparan sulfate, chondroitin sulfate, and hyaluronic acid) concentrations

64 ycosaminoglycans (including heparan sulfate, chondroitin sulfate, and hyaluronic acid) lining the vas

65 labeled with a mature neuron marker, NeuN or chondroitin sulfate antibody, NG2.

66 HS and chondroitin sulfate are also essential.

67 patients, elevated levels of syndecan-1 and chondroitin sulfate are strongly associated with plasma

68 Chondroitin sulfate B PGs appeared to be the primary tar

69 The chondroitin sulfate-bearing proteoglycans, also known as

70 h antibodies HS4C3 (anti-HS) or IO3H10 (anti-chondroitin sulfate), binding was absent, as occurred wh

71 Here I present the structure of the chondroitin sulfate-binding DBL3X domain from a var2csa-

72 biopsies for C4S, CD44 variant 7 (CD44v7), a chondroitin sulfate-binding isoform causally implicated

73 that both enzymes play a significant role in chondroitin sulfate breakdown.

74 The complex is covalently held together by chondroitin sulfate but during inflammation IalphaI may

75 stV-1) suggest a minor role in infection for chondroitin sulfate but not heparin.

76 9 readily infected cells that express excess chondroitin sulfate but that are devoid of heparan sulfa

77 at both HYAL1 and beta-hexosaminidase cleave chondroitin sulfate, but it is a preferred substrate for

78 ted how divalent cations in concert with the chondroitin sulfate chain influence the structure and st

79 The chondroitin sulfate chain interacted with all protein co

80 chain 2, and bikunin covalently joined by a chondroitin sulfate chain originating at Ser-10 of bikun

81 ch has two heavy chains (HC1 and HC2) on its chondroitin sulfate chain.

82 Binding involves the chondroitin sulfate chains and a specific site on the fi

83 ining glycosaminoglycans (GAGs), such as the chondroitin sulfate chains of the proteoglycan versican,

84 ated chondroitin in addition to low-sulfated chondroitin sulfate chains.

85 NE is known to bind to heparan sulfate- and chondroitin sulfate-containing proteoglycans, we treated

86 Versican is a large chondroitin sulfate-containing, hyaluronic acid-binding

87 ated GAGs have been found in marine sponges, chondroitin sulfate (CS) and heparan sulfate (HS) have b

88 identify different isomeric disaccharides of chondroitin sulfate (CS) and heparan sulfate (HS), which

89 Chondroitin sulfate (CS) and the CS-rich extracellular m

90 collagens, were fabricated with and without chondroitin sulfate (CS) and their ability to stimulate

91 on the synthesis of heparan sulfate (HS) and chondroitin sulfate (CS) by murine airway smooth muscle

92 ulfation pattern) at the reducing end of the chondroitin sulfate (CS) chain of bikunin, or the core p

93 kunin is posttranslationally modified with a chondroitin sulfate (CS) chain, O-linked to a serine res

94 hological amounts of hyaluronic acid (HA) or chondroitin sulfate (CS) did not directly increase indic

95 rotein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the pl

96 rsican is a large proteoglycan with numerous chondroitin sulfate (CS) glycosaminoglycan (GAG) side ch

97 Heparan sulfate (HS) and chondroitin sulfate (CS) glycosaminoglycans (GAG) are pr

98 The necessity of heparan sulfate (HS) or chondroitin sulfate (CS) glycosaminoglycans (GAGs) for b

99 modify cell surfaces with specific sulfated chondroitin sulfate (CS) glycosaminoglycans using chemic

100 Chondroitin sulfate (CS) has an important role in cell d

101 Chondroitin sulfate (CS) has been widely used for medica

102 Chondroitin sulfate (CS) is a polysaccharide consisting

103 Chondroitin sulfate (CS) is a sulfated polysaccharide th

104 Chondroitin sulfate (CS) is an important glycosaminoglyc

105 Chondroitin sulfate (CS) is the most abundant component

106 Chondroitin sulfate (CS) modification of versican is a p

107 olved to bind to the glycosaminoglycan (GAG) chondroitin sulfate (CS) on host cells.

108 PC generation by formation of complexes with chondroitin sulfate (CS) on TM.

109 tive incorporation of N-glycolyl groups into chondroitin sulfate (CS) over other potential glycoconju

110 phosphatase zeta (PTP-zeta), a cell surface chondroitin sulfate (CS) proteoglycan, as a novel IL-34

111 Chondroitin sulfate (CS) proteoglycans (CSPGs) are known

112 es of heparan sulfate (HS) proteoglycans and chondroitin sulfate (CS) proteoglycans in the developmen

113 he contributions of hyaluronic acid (HA) and chondroitin sulfate (CS) to glomerular microvascular end

114 (GAG) substrates, dermatan sulfate (DS), and chondroitin sulfate (CS) when the enzyme is taken up int

115 collagenase activity of CatK is promoted by chondroitin sulfate (CS), a sulfated glycosaminoglycan.

116 en to evaluate the effect of glucosamine and chondroitin sulfate (CS), alone or in combination, as we

117 Heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), and HA

118 tion of glycosaminoglycans (GAGs), including chondroitin sulfate (CS), dermatan sulfate (DS), and hep

119 Chondroitin sulfate (CS), heparan sulfate (HS), heparin

120 low molecular weight dextran sulfate (LDS), chondroitin sulfate (CS), heparin (HP), hyaluronic acid

121 hat are covalently bound by an ester bond to chondroitin sulfate (CS), which itself is attached to Se

122 cules and binds to the linear polysaccharide chondroitin sulfate (CS).

123 tions between a specific sulfated epitope on chondroitin sulfate, CS-E, and the neurotrophins, a crit

124 GAG), chondroitin 4-sulfate (C4S), and total chondroitin sulfates (CSs) was measured following immuno

125 es Otx2 binding to PNNs, and specifically to chondroitin sulfate D and E, with high affinity.

126 decrease in the Stokes radius and a bikunin chondroitin sulfate-dependent increase of the thermodyna

127 Further, we predict the pose of heparin and chondroitin sulfate derivatives bound to the axon guidan

128 Accumulation of chondroitin sulfate derivatives was detected in mice def

129 following order: heparin > heparan sulfate > chondroitin sulfate = dermatan sulfate.

130 Heparan sulfate (HS) and chondroitin sulfate/dermatan sulfate (CS/DS) glycosamino

131 Chondroitin sulfate/dermatan sulfate (CS/DS) proteoglyca

132 trated that both XylNapOH- and XylNap-primed chondroitin sulfate/dermatan sulfate GAGs derived from H

133 In contrast, neither the chondroitin sulfate/dermatan sulfate nor the heparan sul

134 irst report on cytotoxic effects mediated by chondroitin sulfate/dermatan sulfate.

135 , heparan sulfate and less sulfated forms of chondroitin sulfate did not augment matrilysin activatio

136 od for the detection and quantification of a chondroitin sulfate disaccharide based on FRET, involvin

137 tions as well as patterns of heparan sulfate/chondroitin sulfate disaccharide sulfation.

138 e, we report the identification of exogenous chondroitin sulfate-E (CS-E) as an inhibitor of specific

139 e demonstrate that a sugar epitope on CSPGs, chondroitin sulfate-E (CS-E), potently inhibits axon gro

140 yaluronic acid, alginates, gelatin, heparin, chondroitin sulfate, etc.) and biodegradable synthetic p

141 Fucosylated chondroitin sulfate (fCS) extracted from the sea cucumbe

142 ediates systemic clearance of hyaluronan and chondroitin sulfates from the vascular and lymphatic cir

143 eparin, and the semisynthetic fully sulfated chondroitin sulfate, FSCS, through a displacement-based

144 g, likely via Wnt sequestration, whereas the chondroitin sulfate GAG chains on TbetaRIII promote Wnt3

145 lycans (GAGs) but not to the closely related chondroitin sulfate GAGs.

146 r that exists with or without heparan and/or chondroitin sulfate glycosaminoglycan (GAG) modification

147 nding and physical entanglements between the chondroitin sulfate-glycosaminoglycan side chains are pr

148 cell types and that the heparan sulfate and chondroitin sulfate glycosaminoglycans serve as attachme

149 ase ABC (Ch'ase ABC) digestion of inhibitory chondroitin sulfate glycosaminoglycans significantly enh

150 d by free HS chains, whereas closely related chondroitin sulfate had no effect.

151 ng of heparan sulfate, dermatan sulfate, and chondroitin sulfate have been identified as heparin cont

152 lfated GAGs was comparable with oversulfated chondroitin sulfate in activating the contact system.

153 fully used for the detection of oversulfated chondroitin sulfate in heparin as a contaminant followin

154 is the primary scavenger receptor for HA and chondroitin sulfates in mammals.

155 neal glycosaminoglycans, keratan sulfate and chondroitin sulfate, in isolation from their core protei

156 dy of known protein partners for heparan and chondroitin sulfate, including fibroblast growth factor

157 l of sialic acid, but not heparan sulfate or chondroitin sulfate, increased AAV9 transduction regardl

158 Furthermore, inclusion of chondroitin sulfate into the fibers enhanced cartilage-s

159 When chondroitin sulfate is added to arabinan-containing cult

160 agen, by (3)H-glucosamine incorporation into chondroitin sulfate, keratan sulfate, and hyaluronan, an

161 tissues [N-terminal, C-terminal (57K), and a chondroitin-sulfate-linked N-terminal fragment (DMP1-PG)

162 tudy, the CS-56 antibody, which recognizes a chondroitin sulfate moiety, labeled a subset of adult br

163 e complexes; indeed, for the highly sulfated chondroitin sulfate motifs, CS-E and CS-D, there are no

164 ads to transfer of the heavy chains from the chondroitin sulfate of inter-alpha-inhibitor to hyaluron

165 var2csa-encoded PfEMP1 protein interact with chondroitin sulfate on the placenta surface.

166 The grafting of chondroitin sulfate on the surface of the scaffold is ab

167 SG1 did not bind to cells lacking heparan or chondroitin sulfate on their surface, and binding was re

168 confidence interval [CI] = 1.001-1.007) and chondroitin sulfate (OR = 1.157; 95% CI = 1.025-1.307) h

169 detection and quantification of oversulfated chondroitin sulfate (OSCS) and other high charge-density

170 tan sulfate (DS) impurities and oversulfated chondroitin sulfate (OSCS) contaminants, proton NMR spec

171 ound to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit

172 example, the rapid detection of oversulfated chondroitin sulfate (OSCS) in heparin could prevent reoc

173 Oversulfated chondroitin sulfate (OSCS) is a harmful contaminant in t

174 ification of the contaminant as oversulfated chondroitin sulfate (OSCS) was reported in our earlier r

175 rgent need to determine whether oversulfated chondroitin sulfate (OSCS), a compound contaminating hep

176 verse effects was identified as oversulfated chondroitin sulfate (OSCS).

177 ned a contaminant identified as oversulfated chondroitin sulfate (OSCS).

178 onse to heparin adulteration by oversulfated chondroitin sulfates (OSCS) that was associated with adv

179 nstrate that a specific sugar epitope within chondroitin sulfate polysaccharides can direct important

180 rs resembling unmodified heparan sulfate and chondroitin sulfate precursor molecules.

181 cy of a fixed combination of xanthan gum and chondroitin sulfate preservative free on the ocular surf

182 Xanthan gum/chondroitin sulfate preservative free showed similar cli

183 arin, heparan sulfate, dermatan sulfate, and chondroitin sulfates produced simple mass spectra consis

184 4 by its natural ligands, hyaluronic acid or chondroitin sulfate, protected CLL cells from apoptosis,

185 Fras1 and AMACO interact directly via their chondroitin sulfate proteoglycan (CSPG) and P2 domains.

186 We found that the axon growth inhibitor chondroitin sulfate proteoglycan (CSPG) strongly inhibit

187 Melanoma chondroitin sulfate proteoglycan (MCSP) is a plasma memb

188 %) of these labeled cells also expressed NG2 chondroitin sulfate proteoglycan (NG2 glia).

189 e proteoglycan versican (VCAN; also known as chondroitin sulfate proteoglycan 2 [CSPG2]).

190 ased apoptosis and impaired proliferation of chondroitin sulfate proteoglycan 4 (also known as neuron

191 Cell surface chondroitin sulfate proteoglycan 4 (CSPG4) is an attract

192 ecursor cells from which they arise, express chondroitin sulfate proteoglycan 4 (NG2/CSPG4).

193 METHODS AND Expression of CSPG4 (chondroitin sulfate proteoglycan 4) was detected in epid

194 onal antibodies specific to cancer biomarker chondroitin sulfate proteoglycan 4, enabling its detecti

195 ealing only two genes, encoding aggrecan and chondroitin sulfate proteoglycan 4, that were selectivel

196 We also identify Neuroglycan C/Chondroitin sulfate proteoglycan 5 (NGC/CSPG5), a potent

197 or CNS endocannabinoid, in the modulation of chondroitin sulfate proteoglycan accumulation in Theiler

198 Here we report that the chondroitin sulfate proteoglycan aggrecan both regulates

199 tin sulfation and abnormal metabolism of the chondroitin sulfate proteoglycan aggrecan.

200 The chondroitin sulfate proteoglycan brevican is a major com

201 ndroitinase ABC, an enzyme that degrades the chondroitin sulfate proteoglycan components of PNNs.

202 CNS, modulates neuroinflammation and reduces chondroitin sulfate proteoglycan deposition around demye

203 ensitive to inhibition by Nogo protein or by chondroitin sulfate proteoglycan in vitro.

204 , we treated rats with the growth-inhibitory chondroitin sulfate proteoglycan neurocan, the growth-st

205 NG2 cells express the chondroitin sulfate proteoglycan NG2 and are a fourth ty

206 Cells expressing the purportedly inhibitory chondroitin sulfate proteoglycan NG2 proliferate in the

207 d expression of chondroitin sulfates and the chondroitin sulfate proteoglycan NG2.

208 evious studies have shown that versican is a chondroitin sulfate proteoglycan of the ECM that is prod

209 growth on myelin-associated glycoprotein and chondroitin sulfate proteoglycan substrates.

210 Zebrafish Decorin is a chondroitin sulfate proteoglycan that exhibits a high de

211 ed antigen (HMW-MAA), also known as melanoma chondroitin sulfate proteoglycan, has been used as a tar

212 e presence of the growth-inhibitory proteins chondroitin sulfate proteoglycan, myelin basic protein,

213 ssing Mfn-2 altered growth cone responses to chondroitin sulfate proteoglycan, netrin-1, and fibronec

214 eparan sulfate proteoglycan glypican, or the chondroitin sulfate proteoglycan-degrading enzyme chondr

215 Survival, proliferation (chondroitin sulfate proteoglycan-NG2(+) and late oligode

216 Chondroitin sulfate proteoglycan-related abnormalities i

217 ss-reactivity against versican V2 isoform, a chondroitin sulfate proteoglycan.

218 rm), and speculate that the higher levels of chondroitin-sulfate proteoglycan (CSPG) in more mature a

219 ich extracellular glycocalyx composed of the chondroitin sulfate-proteoglycan versican bound to a hea

220 the presence of inhibitory molecules, e.g., chondroitin sulfate proteoglycans (CSPG), in the glial s

221 face of infected-erythrocytes, and placental chondroitin sulfate proteoglycans (CSPG).

222 Chondroitin sulfate proteoglycans (CSPGs) accumulate at

223 Chondroitin sulfate proteoglycans (CSPGs) act as barrier

224 environment contains both growth-inhibitory chondroitin sulfate proteoglycans (CSPGs) and growth-pro

225 In the adult mammalian CNS, chondroitin sulfate proteoglycans (CSPGs) and myelin-ass

226 Chondroitin sulfate proteoglycans (CSPGs) are a family o

227 Chondroitin sulfate proteoglycans (CSPGs) are a key stru

228 ellular matrix (ECM) proteoglycans, of which chondroitin sulfate proteoglycans (CSPGs) are a major cl

229 Chondroitin sulfate proteoglycans (CSPGs) are a major cl

230 Chondroitin sulfate proteoglycans (CSPGs) are a major co

231 Chondroitin sulfate proteoglycans (CSPGs) are among the

232 Chondroitin sulfate proteoglycans (CSPGs) are highly exp

233 Chondroitin sulfate proteoglycans (CSPGs) are important

234 Both the sugar chains and core proteins of chondroitin sulfate proteoglycans (CSPGs) are inhibitory

235 Myelin-associated inhibitors (MAIs) and chondroitin sulfate proteoglycans (CSPGs) are major cont

236 Chondroitin sulfate proteoglycans (CSPGs) are thought to

237 and extracellular matrix molecules including chondroitin sulfate proteoglycans (CSPGs) found within t

238 Chondroitin sulfate proteoglycans (CSPGs) have been repo

239 ate proteoglycans (HSPGs), the importance of chondroitin sulfate proteoglycans (CSPGs) in modulating

240 Chondroitin sulfate proteoglycans (CSPGs) inhibit repair

241 Previous studies demonstrated that chondroitin sulfate proteoglycans (CSPGs) on apical surf

242 Chondroitin sulfate proteoglycans (CSPGs) play a pivotal

243 Chondroitin sulfate proteoglycans (CSPGs) present a barr

244 urportedly one of the most growth-inhibitory chondroitin sulfate proteoglycans (CSPGs) produced after

245 Chondroitin sulfate proteoglycans (CSPGs) represent a ma

246 We found that chondroitin sulfate proteoglycans (CSPGs) were present i

247 Chondroitin sulfate proteoglycans (CSPGs), a main compon

248 trocytes form an astroglial scar and produce chondroitin sulfate proteoglycans (CSPGs), activate micr

249 densation with mislocalized distributions of chondroitin sulfate proteoglycans (CSPGs), aggrecan and

250 godendrocyte myelin glycoprotein (OMgp), and chondroitin sulfate proteoglycans (CSPGs), and a key que

251 ction of chondroitinase-ABC, known to digest chondroitin sulfate proteoglycans (CSPGs), prevented the

252 ntaining substantial amounts of glycosylated chondroitin sulfate proteoglycans (CSPGs), whereas glyco

253 ing of the highly upregulated tenascin-C and chondroitin sulfate proteoglycans (CSPGs).

254 receptors that mediate growth inhibition of chondroitin sulfate proteoglycans (CSPGs).

255 the regeneration-inhibiting matrix molecules chondroitin sulfate proteoglycans (CSPGs).

256 Heparan and chondroitin sulfate proteoglycans (HSPGs and CSPGs, resp

257 glycoprotein--or reactive astrocyte-produced chondroitin sulfate proteoglycans activates PARP1, resul

258 r subsequent plating, the hyaluronan-binding chondroitin sulfate proteoglycans aggrecan, neurocan, an

259 ates, including major CNS inhibitors such as chondroitin sulfate proteoglycans and myelin-associated

260 coproteins tenascin-C and tenascin-R and the chondroitin sulfate proteoglycans brevican and neurocan.

261 ies.SIGNIFICANCE STATEMENT The deposition of chondroitin sulfate proteoglycans contributes to the fai

262 lvement of plasma membrane-bound heparan and chondroitin sulfate proteoglycans in cellular uptake of

263 atterns of hyaluronan and hyaluronan-binding chondroitin sulfate proteoglycans in neural stem cells a

264 nting the formation of PNNs, suggesting that chondroitin sulfate proteoglycans in the PNNs control pl

265 ndroitinase ABC (ChABC) to cleave inhibitory chondroitin sulfate proteoglycans in the scar matrix.

266 that removes CS from its core protein in the chondroitin sulfate proteoglycans or by preventing the f

267 Chondroitin sulfate proteoglycans present in the cardiac

268 reas cyclopamine reduced expression of these chondroitin sulfate proteoglycans that are known to be i

269 NG2 belongs to the family of chondroitin sulfate proteoglycans that are upregulated a

270 nets are composed of lecticans, a family of chondroitin sulfate proteoglycans that includes aggrecan

271 e was no increase in the gene expression of "Chondroitin Sulfate Proteoglycans" (CSPGs') clusters.

272 on of inhibitory molecules (such as Nogo and chondroitin sulfate proteoglycans) or administration of

273 rophic factor (GDNF), but not the removal of chondroitin sulfate proteoglycans, greatly enhanced the

274 severe glial scar and enhanced expression of chondroitin sulfate proteoglycans, indicative of a more

275 Results are shown for chondroitin sulfate proteoglycans, low molecular weight

276 the neural matrix is the lectican family of chondroitin sulfate proteoglycans, of which brevican is

277 roblast growth factors, WNT/beta-catenin and chondroitin sulfate-related genes.

278 effect of three putative growth inhibitors--chondroitin sulfate, serum albumin, and transferrin--usi

279 the cysteine-rich domain of MRC binds to the chondroitin sulfate side chains of CD44.

280 rface is, at least in part, dependent on its chondroitin sulfate side chains.

281 ely charged heparin, whereas no reduction in chondroitin sulfate storage was observed.

282 exclusive addition of the glycosaminoglycan chondroitin sulfate, suggesting that factors in the alph

283 A chondroitin sulfate-supplemented diet together with D. p

284 Chondroitin sulfate synthase 1 (Chsy1) is one of a famil

285 a subset of proteins (including IgE, Bank1, chondroitin sulfate synthase 2, Cmip, and Fth1) were exc

286 sis have been identified, and the complex of chondroitin sulfate synthase-1 (CSS1)/chondroitin syntha

287 1 (CSS1)/chondroitin synthase-1 (ChSy-1) and chondroitin sulfate synthase-2 (CSS2)/chondroitin polyme

288 cetylglucosamine (O-GlcNAcylation) on HA and chondroitin sulfate synthesis in primary human aortic sm

289 The sensitivity of oversulfated chondroitin sulfate to five different depolymerization p

290 The transesterification transfer of HCs from chondroitin sulfate to HA is mediated by tumor necrosis

291 aminoglycan side chains of either heparin or chondroitin sulfate type, and large amounts of positivel

292 d ratio between proteoglycans of heparin and chondroitin sulfate type, with increased amounts of hepa

293 In contrast, chondroitin sulfate types A, C, D, and E did not stimula

294 dermatan sulfate (DS), apoptotic debris, and chondroitin sulfate types A, C, D, and E.

295 The four nonstimulatory chondroitin sulfate types, which compete for HA binding,

296 faster on the two native GAGs, one of which, chondroitin sulfate, was also characterized by the highe

297 a chondroitin lyase; although its substrate, chondroitin sulfate, was previously thought to be an ani

298 microm thickness) only after hyaluronan and chondroitin sulfate were added to the cell culture media

299 ian glycosaminoglycan (DHG) is a fucosylated chondroitin sulfate with antithrombin-independent antith

300 f poly(vinyl alcohol) and the biological cue chondroitin sulfate with fiber dimensions on the nanosca